Toll-like receptor 5 agonist inhibition of growth of A549 lung cancer cells in vivo in a MyD88 dependent manner

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 6, 2012, Pages 2807-2812

  Zhou, Shi Xiang ^a   Li, Feng Sheng ^a,b   Qiao, Yu Lei ^a   Zhang, Xue Qing ^a   Wang, Zhi Dong ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b Second Artillery Corps General Hospital   (China)

Author keywords

CBLB502; Lung cancer; TLR5 agonist; Tumor suppressor

Indexed keywords

EID: 84874004337     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.6.2807     Document Type: Article

References (27)

1. Armant MA, Fenton MJ (2002). Toll-like receptors: a family of pattern-recognition receptors in mammals. Genome Biol, 3, REVIEWS3011.
2. Bickels J, Kollender Y, Merinsky O, Meller I (2002). Coley's toxin: historical perspective. Isr Med Assoc J, 4, 471-2.
3. Burdelya LG, Krivokrysenko VI, Tallant TC, et al (2008). An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science, 320, 226-30
4. Challacombe JM, Suhrbier A, Parsons PG, et al (2006). Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol, 177, 8123-32.
5. Cheng YS, Xu F (2011). Anticancer function of polyinosinicpolycytidylic acid. Cancer Biol Ther, 10, 1219-23.
6. Di CE, Forni G, Lollini P, et al (2001). The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood, 97, 339-45.
7. Gewirtz AT, Navas TA, Lyons S, Godowski PJ, Madara JL (2001). Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol, 167, 1882-5.
8. Hartman ZC, Osada T, Glass O, et al (2010). Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity. Cancer Res, 70, 7209-20.
9. Hicks AM, Riedlinger G, Willingham MC, et al (2006). Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci USA, 103, 7753-8.
10. Kanzler H, Barrat FJ, Hessel EM, Coffman RL (2007). Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med, 13, 552-9.
11. Kawai T, Akira S (2006). TLR signaling. Cell Death Differ, 13, 816-25.
12. Kawai T, Akira S (2010). The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol, 11, 373-84.
13. Khoo JJ, Forster S, Mansell A (2011). Toll-like receptors as interferon-regulated genes and their role in disease. J Interferon Cytokine Res, 31, 13-25.
14. Lin YS, Huang LD, Lin CH, et al (2011). In vitro and in vivo anticancer activity of a synthetic glycolipid as TLR4 activator. J Biol Chem, (in press).
15. Narayanan P, Lapteva N, Seethammagari M, et al (2011). A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. J Clin Invest, 121, 1524-34.
16. Nozawa H, Chiu C, Hanahan D (2006). Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA, 103, 12493-8.
17. Ostberg JR, Ertel BR, Lanphere JA (2005). An important role for granulocytes in the thermal regulation of colon tumor growth. Immunol Invest, 34, 259-72.
18. Rhee SH, Im E, Pothoulakis C (2008). Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology, 135, 518-28.
19. Rhee SH, Im E, Riegler M, et al (2005). Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation. Proc Natl Acad Sci USA, 102, 13610-5.
20. Rhee SH, Kim H, Moyer MP, Pothoulakis C (2006). Role of MyD88 in phosphatidylinositol 3-kinase activation by flagellin/toll-like receptor 5 engagement in colonic epithelial cells. J Biol Chem, 281, 18560-8.
21. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T (2006). TLR3 can directly trigger apoptosis in human cancer cells. J Immunol, 176, 4894-901.
22. Thomas JA, Badini M (2011). The role of innate immunity in spontaneous regression of cancer. Indian J Cancer, 48, 246-51.
23. Tse BW, Russell PJ, Lochner M, Forster I, Power CA (2011). IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanisms. PLoS ONE, 6, e24241.
24. Wolska A, Lech-Maranda E, Robak T (2009). Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett, 14, 248-72.
25. Xie Q, Gan L, Wang J, Wilson I, Li L (2007). Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth. Mol Immunol, 44, 3453-61.
26. Zhang Y, Luo F, Cai Y, et al (2011). TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. J Immunol, 186, 1963-9.
27. Zhang Y, Sun R, Liu B, et al (2009). TLR3 activation inhibits nasopharyngeal carcinoma metastasis via downregulation of chemokine receptor CXCR4. Cancer Biol Ther, 8, 1826-30.